Search / Trial NCT06227481

Combined Procedures in the Treatment of Severe Acne Scars

Launched by AL-AZHAR UNIVERSITY · Jan 25, 2024

Trial Information

Current as of December 22, 2024

Not yet recruiting

Keywords

ClinConnect Summary

This is a prospective controlled trial that will be conducted at Dermatology, venereology, and andrology Department, Al-Azhar university hospital, Assiut, in the period from March 2024 to March 2026, to assess the efficacy of combination of scar subcision with platelet rich plasma , polydioxanone mono threads or fractional carbon dioxide laser in the treatment of severe atrophic acne scars with 1:1:1 ratios and to compare between these modalities regarding safety and efficacy

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • • Patients with severe atrophic acne scars (as per Goodman and Baron's acne qualitative scar grading scale)
  • Exclusion Criteria:
  • Patients with active acne lesions.
  • Patients having a keloid formation tendency.
  • Patients with a history of bleeding disorder or severe anemia.
  • Pregnant or lactating women.
  • Patients received any treatment for scars in the last 6 months.
  • Patients using drugs causing photosensitivity or systemic retinoids in the previous 6 months (for laser group).

Trial Officials

Essam-Eldin M Mohamed, MD

Study Director

ALAZHAR UNIVERSITY

About Al Azhar University

Al-Azhar University, a prestigious institution in Egypt, is dedicated to advancing medical research and education through rigorous clinical trials. With a strong emphasis on ethical standards and scientific integrity, the university aims to contribute to the development of innovative therapies and healthcare solutions. By fostering collaboration among researchers, healthcare professionals, and academic experts, Al-Azhar University positions itself as a leading sponsor in clinical research, committed to improving patient outcomes and enhancing the understanding of various medical conditions.

Locations

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0